John C. Byrd, M.D.

John C. Byrd, M.D., is an internationally known researcher and clinical specialist

in leukemia and other hematologic malignancies. He currently is the Chair of the

Department of Internal Medicine at the University of Cincinnati. He holds the

Gordon and Helen Hughes Taylor Chair. Outside of his academic roles, Dr. Byrd

is a principal and Chief Medical Officer of Beat AML, an LLC of the Leukemia

and Lymphoma Society. The Beat AML study has brought together multiple industry, academic, and governmental stakeholders to move precision medicine in AML forward in the United States.

Dr. Byrd received his medical degree from the University of Arkansas for Medical Sciences. His education continued in internal medicine and hematology and

oncology at Walter Reed Army Medical Center and Johns Hopkins University

before moving to Columbus to join the faculty at Ohio State where he developed an internationally recognized blood cancer program and was the founding director of the Division of Hematology.

He moved to the University of Cincinnati in 2021 as Chairman of Internal Medicine and also to contribute to building an NCI designated cancer center. Dr. Byrd runs a

highly translational laboratory and early drug development program focused on CLL and

new therapeutics in hematologic malignancies. He has been part of the successful development of multiple therapeutics in blood cancers, most notably the Bruton’s Tyrosine kinase inhibitors (ibrutinib and acalabrutinib). He has over 650 publications, has been continuously funded by the NIH for over two decades, and has received multiple awards for his contribution to drug development in blood cancers. Dr. Byrd also currently chairs or serves as a member on multiple pharmaceutical company scientific advisory boards and has founded two companies stemming from his work.